Develops Plinabulin and other drug candidates for cancer patients, and works with pharmaceutical companies on medicines that target proteins for breakdown.
10-K for FY2025, filed Mar 25, 2026
Pharmaceutical companies collaborate on drug discovery and commercialization: Hengrui is the Plinabulin commercialization partner in Greater China, while Eli Lilly and Eisai work with SEED on drug discovery.
10-K for FY2025, filed Mar 25, 2026
10-Q for Q2 FY2026, filed Aug 14, 2026
−$849KView ↗
8-K, filed Sep 18, 2026
Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company is provided with a compliance period of 180 calendar days from the date of the…View ↗
8-K, filed Jun 4, 2026
Dr. Lan Huang, the current Chief Executive Officer and Chair of the Board of Directors (the “Board”) of the Company, will transition from…View ↗
SEED's pipeline advances
SEED's earlier description centered on its drug-discovery platform and collaborations; the latest report says its wholly owned lead oncology drug has entered clinical studies.
20-F for FY2022, filed Apr 18, 2023 10-K for FY2025, filed Mar 25, 2026We are a clinical stage global biopharmaceutical company focused on using its novel technology platform for drug discovery and development…View ↗
We are a clinical stage global biopharmaceutical company focused on developing innovative therapies to improve clinical outcomes for…View ↗
Competes with Bristol-Myers Squibb, Merck &, and Eli Lilly
10-K for FY2025, filed Mar 25, 2026There are a number of large pharmaceutical and biotechnology companies that currently market and sell drugs or are pursuing the development…View ↗
Loading...